

Enzychem Lifesciences completes Stage 1 patient enrollment in Ph2 CRIOM study

22 February 2019 | News

Stage 1 of the Phase 2 CRIOM study evaluates the maximum tolerable dose of EC-18 which will be used in Stage 2of the study.



Enzychem Lifesciences, a global biopharmaceutical company headquartered in Seoul, Korea which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients) has announced that the company has achieved a huge milestone by completing enrollment of the required 24 patients in Stage 1 of the Phase 2 CRIOM (Chemoradiation Induced Oral Mucositis) study.

Stage 1 of the Phase 2 CRIOM study evaluates the maximum tolerable dose of EC-18 which will be used in Stage 2 of the study. Patient enrollment for Stage 2 is expected to begin in 2Q 2019. Enzychem has received Fast Track Designation by the U.S. Food and Drug Administration for the Phase 2 study evaluating lead investigational candidate EC-18 in CRIOM.

Enzychem's lead investigational candidate EC-18, is in development for a variety of indications including Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). Enzychem Lifesciences was awarded U.S. FDA Fast Track Designation for EC-18 in CRIOM and FDA Orphan Drug Designation in ARS. CIN and CRIOM are in Phase II clinical trials and a pivotal study evaluating EC-18 in ARS is expected to begin under FDA's animal rule guidance.

EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). In order to facilitate the clinical trial process, Enzychem launched a US operation office in New Jersey on June 28, 2018.